Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › prasugrel

prasugrel

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of prasugrel

35 trials tracked of prasugrel: 20 in phase 3 or 4 and 9 with published results. The most-cited published study has 683 citations.

35Trials tracked
20Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 13 Phase 3 7 Phase 2 8 Phase 1 4 Other / NA 3
  1. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 683 cited
  2. Phase 4 Pharmacological Effects of Crushing Prasugrel in STEMI Patients Completed · 124 cited
  3. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 76 cited
  4. Phase 4 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: Completed · 28 cited
  5. Phase 4 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Completed · 22 cited
  6. Phase 4 Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI Completed · 21 cited
Show 29 more trials
  1. Phase 4 Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Completed · 15 cited
  2. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  3. Phase 4 Clopidogrel Monotherapy in Patients With High Bleeding Risk Completed · 2 cited
  4. Phase 4 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation Completed
  5. Phase 4 P3AMI Antiplatelet Trial Completed
  6. Phase 4 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study Completed
  7. Phase 4 Prasugrel Re-load Strategies Completed
  8. Phase 4 Prasugrel/Clopidogrel Maintenance Dose Washout Study Completed
  9. Phase 4 The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease Completed
  10. Phase 3 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis Completed
  11. Phase 3 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome Completed
  12. Phase 3 A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction Completed
  13. Phase 3 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed
  14. Phase 3 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Completed
  15. Phase 2 Cangrelor to Clopidogrel or Prasugrel Transition Study Completed
  16. Phase 2 Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting Completed
  17. Phase 2 Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients Completed
  18. Phase 2 Prasugrel Versus Placebo in Adult Sickle Cell Disease Completed
  19. Phase 2 Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3) Completed
  20. Phase 2 Cangrelor Prasugrel Transition Study Completed
  21. Phase 2 A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease Completed
  22. Phase 2 The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS) Completed
  23. Phase 1 Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease Completed
  24. Phase 1 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults Completed
  25. Phase 1 Study of Prasugrel in Korean Healthy Male Volunteers Completed
  26. Phase 1 Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease Completed
  27. N/A Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes Completed
  28. N/A TAXUS Libertē Post Approval Study Completed
  29. N/A Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes
Cardiology Meta-analysis
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes Trial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients
This meta-analysis of 60,619 patients following percutaneous coronary intervention evaluates P2Y12 inhibitors using a Bayesian framework. Th…
A large analysis of over 60,000 patients suggests prasugrel may be more effective than clopidogrel for preventing major heart events after p…
medRxiv Sep 7, 2026
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy
Cardiology RCT
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy Complex heart procedures do not change risks of certain medications
A post hoc analysis of the NEO-MINDSET trial evaluates if PCI complexity influences the safety and efficacy of potent P2Y inhibitor monother…
New analysis shows that complex heart procedures do not change the safety or effectiveness of specific blood-thinning medications.
Sep 2, 2026
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients
Cardiology RCT
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients New stent type shows promise for patients with diabetes and heart disease
A multicenter trial confirms that ultra-thin biodegradable polymer sirolimus-eluting stents meet noninferiority goals compared to durable po…
A new ultra-thin stent may offer a reliable option for people with both diabetes and complex heart disease.
Aug 27, 2026
Ticagrelor and prasugrel show no statistically credible difference in 1-year MACE for ACS patients
Cardiology Meta-analysis
Ticagrelor and prasugrel show no statistically credible difference in 1-year MACE for ACS patients Comparing Ticagrelor and Prasugrel for Patients with Heart Conditions After Surgery
This meta-analysis of retrospective new-user cohort studies analyzed 133,718 adults with acute coronary syndrome undergoing first PCI. The s…
A large study compared two heart medications to see which was safer and more effective for patients after a heart procedure.
medRxiv Aug 17, 2026
VerifyNow-guided antiplatelet modification linked to lower stroke recurrence in atherothrombotic or lacunar infarction
Neurology RCT
VerifyNow-guided antiplatelet modification linked to lower stroke recurrence in atherothrombotic or lacunar infarction Testing Blood Saves Stroke Patients From Recurrence
A retrospective observational study of 243 patients with atherothrombotic or lacunar infarction found that VerifyNow-guided antiplatelet the…
Doctors who adjusted blood thinner choices based on a simple blood test saw far fewer repeat strokes in patients with prior clots.
medRxiv Apr 16, 2026
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI
Cardiology RCT
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI New study shows ticagrelor did not beat prasugrel for heart attack prevention in diabetics
This randomized clinical trial of 1,800 patients with diabetes and multivessel coronary artery disease undergoing PCI compared ticagrelor pl…
For diabetics with heart stents, a new study found ticagrelor offered no clear advantage over prasugrel in preventing death, heart attacks, …
JAMA Cardiol Apr 9, 2026
Early Aspirin Withdrawal Post-PCI Reduces Bleeding, No MI Increase with P2Y12 Monotherapy
Cardiology Meta-analysis
Early Aspirin Withdrawal Post-PCI Reduces Bleeding, No MI Increase with P2Y12 Monotherapy Could Stopping Aspirin Early Help Heart Patients Avoid Bleeding Risks?
Meta-analysis shows early aspirin withdrawal (≤3 months) post-PCI with ticagrelor/prasugrel reduces bleeding (HR=0.55, 95% CI [0.42, 0.71]; …
Stopping aspirin within three months after a heart procedure reduces bleeding risk without increasing heart attack chances for many patients…
Mar 27, 2026